New Phase 3 Data Show BEM/RZR Noninferior to Epclusa for Hep C

Originally published by our sister publication Infectious Disease Special EditionBy Meaghan Lee CallaghanBemnifosbuvir/ruzasvir (BEM/RZR; Atea) has met its primary and secondary end points in the phase 3 C-BEYOND trial in patients with hepatitis C, showing noninferiority to standard-of-care sofosbuvir/velpatasvir (SOF/VEL; Epclusa, Gilead), according to the drugmaker.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure im